BioCentury
ARTICLE | Clinical News

TKM-PLK1: Additional Phase I data

October 21, 2013 7:00 AM UTC

Additional data from an open-label, dose-escalation, U.S. Phase I trial showed that 6 of 15 evaluable patients receiving IV TKM-PLK1 at doses of >=0.6 mg/kg showed a clinical benefit. There were 3 cases of stable disease in 4 evaluable patients with adrenocortical carcinoma, including 1 patient who achieved a 19.3% reduction in tumor size. Of 2 patients with advanced gastrointestinal neuroendocrine tumors (GI-NETs), 1 patient had a partial response and 1 patient had stable disease with a >50% reduction in chromogranin A levels. Tekmira said lowered levels of chromogranin A are linked to improved survival and favorable response to treatment in patients with neuroendocrine tumors. The trial enrolled 36 patients with advanced solid tumors to receive once-weekly 0.15 to 0.9 mg/kg IV TKM-PLK1, including a 10-patient expansion cohort receiving the MTD of 0.75 mg/kg TKM-PLK1. Data were presented at the North American Neuroendocrine Tumor Society meeting in Charleston. ...